KOCHHAR CANCER RESEARCH FOUNDATION

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2004

Legal Domicile

Principal Officer

Ruby Kochhar MD

Phone

3188617153

Tax Period

2025-01-01 to 2025-12-31

KOCHHAR CANCER RESEARCH FOUNDATION, founded in 2004, is a small nonprofit in the Medical Research sector that reported $774K in total revenue in fiscal year 2025. Revenue fell 87% from the prior year — a significant decline worth monitoring. Expenses of $1.3M exceeded revenue, resulting in a 65% operating deficit.

Mission

To develop cancer vaccines and to test these vaccines in cancer mouse models for the prevention and treatment of cancer

Program Service Accomplishments

Program 1

Expenses: $263,851 Revenue: $4,001

Bought special mice for testing the vaccines and housed the mice in the facility

Program 2

Expenses: $1,017,422 Revenue: $2,090

Testing of cancer vaccines in mice is ongoing

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $4,001

Program Service Revenue $2,090

Investment Income $768,135

Other Revenue $0

TOTAL REVENUE $774,226

Expense Breakdown

Grants Paid $0

Salaries & Benefits $887,524

Fundraising Expenses $0

Program Expenses $1,281,273

Other Expenses $393,749

TOTAL EXPENSES $1,281,273

Year-over-Year Comparison

	2025	2024	Change
Revenue	$774,226	$6,122,150	-0.9%
Expenses	$1,281,273	$2,892,881	-0.6%
Net Income	$-507,047	$3,229,269	-1.2%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

$887,524

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Ruby Kochhar MD	President	60.00	Director	$887,524	$0	$887,524
Jay Umbreit MD PhD	Board Member	0.25	Officer	$0	$0	$0
Mark Wilkowski MD	Board Member	0.25	Officer	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$774,226	$1,281,273	$7,469,084	$-507,047
2024	No data	No data	No data	No data
2023	$3,106,694	$27,718	$3,493,307	$3,078,976